These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

578 related articles for article (PubMed ID: 23610452)

  • 1. Review of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker?
    Matthys F; De Backer T; De Backer G; Stichele RV
    Eur J Prev Cardiol; 2014 Mar; 21(3):354-65. PubMed ID: 23610452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan.
    Morimoto T; Fukui T; Lee TH; Matsui K
    Am J Med; 2004 Oct; 117(7):459-68. PubMed ID: 15464702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis.
    Halvorsen S; Andreotti F; ten Berg JM; Cattaneo M; Coccheri S; Marchioli R; Morais J; Verheugt FW; De Caterina R
    J Am Coll Cardiol; 2014 Jul; 64(3):319-27. PubMed ID: 25034070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aspirin for primary prevention of cardiovascular disease events.
    Nemerovski CW; Salinitri FD; Morbitzer KA; Moser LR
    Pharmacotherapy; 2012 Nov; 32(11):1020-35. PubMed ID: 23019080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk.
    Volpe M; Battistoni A; Gallo G; Coluccia R; De Caterina R
    High Blood Press Cardiovasc Prev; 2017 Sep; 24(3):331-339. PubMed ID: 28573479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Italian intersocietary consensus document on aspirin therapy in primary cardiovascular prevention].
    Volpe M; Abrignani MG; Borghi C; Coccheri S; Gresele P; Patti G; Trimarco B; De Caterina R
    G Ital Cardiol (Rome); 2014; 15(7-8):442-51. PubMed ID: 25174598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the risk/benefit profile before recommending aspirin for the primary prevention of cardiovascular events.
    Rodondi N; Bauer DC
    Am J Med; 2004 Oct; 117(7):528-30. PubMed ID: 15464713
    [No Abstract]   [Full Text] [Related]  

  • 8. Are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries?
    Noubiap JJ; Nansseu JR
    Vasc Health Risk Manag; 2015; 11():503-6. PubMed ID: 26345154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What have we learned about using aspirin for primary prevention from the ASCEND and ARRIVE trials?
    Tousoulis D
    Cardiovasc Res; 2019 Feb; 115(2):e15-e16. PubMed ID: 30668678
    [No Abstract]   [Full Text] [Related]  

  • 10. Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis.
    Butalia S; Leung AA; Ghali WA; Rabi DM
    Cardiovasc Diabetol; 2011 Apr; 10():25. PubMed ID: 21453547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AAA- a further step towards a moratorium for aspirin in the primary prevention.
    Minar E
    Vasa; 2010 May; 39(2):119-122. PubMed ID: 20521434
    [No Abstract]   [Full Text] [Related]  

  • 12. Aspirin for the primary prevention of cardiovascular events: recommendations and rationale.
    U.S. Preventive Services Task Force
    Am J Nurs; 2002 Mar; 102(3):67, 69-70. PubMed ID: 11976531
    [No Abstract]   [Full Text] [Related]  

  • 13. Aspirin for primary prevention: yes or no?
    Selak V; Elley CR; Wells S; Rodgers A; Sharpe N
    J Prim Health Care; 2010 Jun; 2(2):92-9. PubMed ID: 20690297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translating guidelines to practice: findings from a multidisciplinary preventive cardiology programme in the west of Ireland.
    Gibson I; Flaherty G; Cormican S; Jones J; Kerins C; Walsh AM; Costello C; Windle J; Connolly S; Crowley J
    Eur J Prev Cardiol; 2014 Mar; 21(3):366-76. PubMed ID: 23884981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin for primary cardiovascular disease prevention: time to re-evaluate guidelines?
    Barmanray R; Hamblin PS
    Intern Med J; 2019 Jan; 49(1):133-134. PubMed ID: 30680892
    [No Abstract]   [Full Text] [Related]  

  • 16. The cardiovascular polypill in high-risk patients.
    Lafeber M; Spiering W; Singh K; Guggilla RK; Patil V; Webster R;
    Eur J Prev Cardiol; 2012 Dec; 19(6):1234-42. PubMed ID: 22019908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspirin in primary prevention: USPSTF recommendations.
    Aalbers J
    Cardiovasc J Afr; 2010; 21(3):176. PubMed ID: 20532445
    [No Abstract]   [Full Text] [Related]  

  • 18. [Aspirin in primary prevention of cardiovascular diseases: how to balance risks and benefits].
    De Caterina R; Orlando D; Berti V; Coccheri S
    G Ital Cardiol (Rome); 2012; 13(7-8):494-502. PubMed ID: 22781376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The New 2019 AHA/ACC Guideline on the Primary Prevention of Cardiovascular Disease.
    Bittner V
    Circulation; 2020 Dec; 142(25):2402-2404. PubMed ID: 30879338
    [No Abstract]   [Full Text] [Related]  

  • 20. A national survey on aspirin patterns of use and persistence in community outpatients in Italy.
    Filippi A; Bianchi C; Parazzini F; Cricelli C; Sessa E; Mazzaglia G
    Eur J Cardiovasc Prev Rehabil; 2011 Oct; 18(5):695-703. PubMed ID: 21450601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.